Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174459 | 0.86 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1906224 | 0.86 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1908412 | 0.85 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL1908182 | 0.84 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1908404 | 0.84 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1897537 | 0.83 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1907094 | 0.82 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL1899395 | 0.82 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL1906857 | 0.81 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11HPGD | |
| SCHEMBL1898336 | 0.80 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4684515-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| US-6541670-B2 | Antiinflammatory agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-01 | — | — | US | claimed |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-01-16 | — | — | US | claimed |
| EP-1237845-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-09-11 | — | — | EP | claimed |
| WO-2001042189-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| EP-1237845-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-6541670-B2 | Antiinflammatory agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-01 | — | — | US | disclosed |
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013770-A1 | Aminobenzophenones as inhibitors of il 1b and tnf | IL1B, IL1A, IL6 | MAPK14 1553/4885MAPK13 2221/4885MAPK12 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.